A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Trial Details

NCT ID

NCT07221357

Phase

PHASE2 / PHASE3

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Pumitamig
• FOLFOX
• FOLFIRI
• Bevacizumab
• CAPOX

Locations (sample)

• Tucson, Arizona, United States|32.22174,-110.92648
• Springdale, Arkansas, United States|36.18674,-94.12881
• Los Angeles, California, United States|34.05223,-118.24368
• Orange, California, United States|33.78779,-117.85311
• San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

• Participant must previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma, not amenable to curative surgery.
• Participant must have no known presence of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) per …
• Participant must have no known presence of the gene that encodes the protein B-Raf (BRAF) V600E mutation per local testing.
• Participant must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.